Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map

Neurodegenerative diseases represent a major public health challenge due to their high prevalence and poor prognosis. Identifying biomarkers to stratify individuals by their risk of developing these diseases may help to define new personalized prevention interventions. The objective of this study was to conduct a scoping review of biomarkers for primary and secondary personalized prevention of neurodegenerative diseases. The search targeted biomarkers in adults or high-risk subpopulations in clinical or public health settings for Alzheimer's disease, vascular dementia, Lewy body disease, frontotemporal dementia, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Ultimately, 286 papers were included in the review and the interactive gap map. There is a strong focus on Alzheimer's disease, and most papers included -omics-based biomarkers and/or used artificial intelligence. Genetics/genomics are at the forefront of current scientific research, although there is a notable gap in studying gene-environment interactions, and studies in clinical settings are still scarce. HIGHLIGHTS: Research indicates a strong focus on Alzheimer´s disease and limited research in other diseases. Genetics and genomics are at the forefront of current scientific research. We found biomarkers for predicting progression in mild cognitive decline. There is a notable gap in studying gene-environment interactions. Studies investigating biomarkers in a clinical context are still scarce.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz.70980
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map

Chaitanya Erady, Laura Blackburn, Ester García‐Ovejero, Ramon Cierco Jiménez et al.
Alzheimer s & Dementia
Amyotrophic Lateral Sclerosis Research
article

Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map

Chaitanya Erady, Laura Blackburn, Ester García‐Ovejero, Ramon Cierco Jiménez, Mark Kroese, Marina Pollán, Fernando Rodríguez‐Artalejo, Patricia Diez‐Echave, Vı́ctor Moreno, Elena Plans‐Beriso, Nicolás Francisco Fernández‐Martínez, Esther García‐Esquinas, Beatriz Pérez‐Gómez, Heather Turner, Hayley Wilson, Dafina Petrova, Pablo Fernández‐Navarro, Isla Kuhn, Oana Craciun, Chantal Babb‐de‐Villiers, Cristina Barahona‐López, María‐José Sánchez, Orlando Hernández, Pascual Sesma Sánchez, Nerea Fernández de Larrea, Estíbaliz Arruabarrena‐Blanco
article en

Abstract

Neurodegenerative diseases represent a major public health challenge due to their high prevalence and poor prognosis. Identifying biomarkers to stratify individuals by their risk of developing these diseases may help to define new personalized prevention interventions. The objective of this study was to conduct a scoping review of biomarkers for primary and secondary personalized prevention of neurodegenerative diseases. The search targeted biomarkers in adults or high-risk subpopulations in clinical or public health settings for Alzheimer's disease, vascular dementia, Lewy body disease, frontotemporal dementia, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Ultimately, 286 papers were included in the review and the interactive gap map. There is a strong focus on Alzheimer's disease, and most papers included -omics-based biomarkers and/or used artificial intelligence. Genetics/genomics are at the forefront of current scientific research, although there is a notable gap in studying gene-environment interactions, and studies in clinical settings are still scarce. HIGHLIGHTS: Research indicates a strong focus on Alzheimer´s disease and limited research in other diseases. Genetics and genomics are at the forefront of current scientific research. We found biomarkers for predicting progression in mild cognitive decline. There is a notable gap in studying gene-environment interactions. Studies investigating biomarkers in a clinical context are still scarce.

Alzheimer s & DementiaVol. 21(12)
Madrid Institute for Advanced Studies (ES), Institut Català d'Ornitologia (ES), Instituto de Salud Carlos III (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Cambridge School (PT), Centro Nacional de Sanidad Ambiental (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital Universitario Virgen de las Nieves (ES), PHG Foundation (GB), Fundacion Centro De Investigacion De Enfermedades Neurologicas (ES), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), Centre international de recherche sur le cancer (FR), Andalusian School of Public Health (ES), Universidad Autónoma de Madrid (ES)
UK Research and Innovation, European Commission, Horizon 2020 Framework Programme, HORIZON EUROPE Framework Programme, Agencia Estatal de Investigación, H2020 Health
Openalex Percentile: Top 46%
Amyotrophic Lateral Sclerosis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.